An interventional study of Doublebase Once in Ichthyosis, sponsored by Dermal Laboratories Ltd. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Dermal Laboratories Ltd · Not applicable, Interventional, and Treatment
28 Day Survey study in patients with Ichthyosis
Ichthyosis patients registered on the ISG/MHF database or patients responding to information on the websites will be advised about the study and asked if they maybe interested in trying Doublebase Once. Any patients interested in taking part will then be asked to register, by completing a short questionnaire that will be used as a pre-screen tool to exclude any patients who are ineligible for the study.
Patients will then be provided with the Patient Information Sheet (PIS) to read and then complete a consent questionnaire confirming their agreement to participate in the study. Once consent has been obtained, patients will then complete a screening questionnaire. ISG/MHF and the Sponsor will require access to personal information such as email addresses (for sending the questionnaires and safety monitoring) and home addresses (for sending the packs of Doublebase Once), but these details will be used solely for the purpose of the study.
If all screening questions are completed and the patient is eligible in accordance with the inclusion and exclusion criteria, the patient will then be sent two pump packs of Doublebase Once 500g.
On receipt of their pack(s) of Doublebase Once (Day 0), the patients will be asked to read through all the information provided and to complete an online questionnaire and, if they agreed at consent, they will be asked to photograph one area of their ichthyosis that will be treated with the product and upload to the database alongside their questionnaire. Guidance on taking the photos will be provided in the questionnaire with regards to, lighting, location, distance, angle of taking photographs and background. This questionnaire and image(s) will form the baseline 'before using Doublebase Once' and there will be some questions to be completed immediately after first use of the product.
Patients will then be asked to use Doublebase Once, as per the package leaflet for approximately 4 weeks, once daily (unless they need to use it more often) and on one area affected by ichthyosis, instead of their usual leave-on emollient. If, during the study patients find that they like using Doublebase Once, they can use the product on all affected areas. Patients will also be asked to use Doublebase Once instead of their usual wash product. If patients do not want to use Doublebase Once instead of their usual wash products, they will be asked to continue to use their usual products.
While using the product, the patients will be sent further questionnaires to complete on Day 8 and 29 and if they consented to do so, to send further photographs of the same area taken at Day 0.
At the end of the study as part of the final questionnaire, patients will be asked to provide a short review about Doublebase Once and give the product a 'star rating' out of 5 (5 being excellent and 1 being poor).
33 studies on the registry are indexed under Ichthyosis; 11 are open to participants now.
This study's planned enrollment of 100 is above the median of 26 across 23 interventional studies indexed under Ichthyosis.
Browse Ichthyosis studies →Dermal Laboratories Ltd is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open label
Device: Doublebase Once
Single daily use Emollient
Questionnaire responses
Skin condition changes from baseline parameters scores 0-10 (0 = strongly agree, 10 = Strongly disagree) and product use questionnaires
Time frame: 4 weeks
No study locations are listed for this record.
Plan to share: Yes — Questionnaire responses
Supporting information: Study protocol, Statistical analysis plan
Time frame: Jan 2027
Access criteria: This registry and Publications
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dermal Laboratories Ltd